Novo Nordisk Wegovy manufactured by Novo Nordisk packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on April 8, 2024. (Photo by Jakub Porzycki/NurPhoto via Getty Images)Novo Nordisk on Wednesday posted weaker-than-expected net profit in the second quarter and trimmed its operating profit outlook.The pharmaceutical giant said its net profit came in at 20.05 billion Danish kroner ($2.93 billion) in the three months to the end of June. A LSEG aggregate forecast had projected the ...

Bagsværd, 7 August 2024 - Financial report for the period 1 January 2024 to 30 June 2024 Operating profit increased by 18% in Danish kroner and by 19% at constant exchange rates (CER) to DKK 57.8 billion. Operating profit is impacted by the impairment loss related to ocedurenone of DKK 5.7 billion. Sales in North America Operations increased by 36% in Danish kroner (36% at CER). Sales growth in the US was positively impacted by gross-to-net sales adjustments related to prior years. Sales in International Op ...

It's not hard to envision how all three of these stocks can deliver exceptional growth.What are the best stocks? Usually, the ones that have clear paths to success.Three Motley Fool contributors have identified what they believe are unstoppable stocks to buy in August. And they all happen to be biotech and pharma companies. Here's why they picked Novo Nordisk (NVO -3.75%), Vertex Pharmaceuticals (VRTX -2.24%), and Viking Therapeutics (VKTX -2.93%).There's still plenty more room to growDavid Jagielski (Novo ...

Novo Nordisk (NVO) ended the recent trading session at $128.05, demonstrating a +1.04% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily gain of 0.08%. Elsewhere, the Dow saw a downswing of 0.12%, while the tech-heavy Nasdaq appreciated by 0.07%.The drugmaker's shares have seen a decrease of 11.22% over the last month, not keeping up with the Medical sector's gain of 0.48% and the S&P 500's loss of 0.21%.Market participants will be closely following t ...

Bagsværd, Denmark, 29 July 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme initiated 6 May 202 ...

Ozempic could pile up a lot more indications in the years ahead.Novo Nordisk (NVO -0.88%) has become one of the most valuable healthcare stocks in the world due in large part to Ozempic, its diabetes drug that has also been effective in helping people lose weight. One challenge for investors and analysts, however, is predicting just how much revenue it could bring in at its peak. As new studies emerge involving the drug, there are new possible benefits uncovered relating to the use of Ozempic.Recently, ther ...

The company should maintain its lead in this growing area.Novo Nordisk (NVO -0.88%) is under attack. Although the Denmark-based drugmaker is a pioneer and leader in the GLP-1 diabetes and weight loss drug markets, countless companies are trying to steal its lunch. It's no wonder: Ozempic, a diabetes medicine, and Wegovy, a weight loss therapy with the same active ingredient, have both seen incredible success. Challengers were bound to rise, eventually. However, Novo Nordisk is also working on potential succ ...

Novo Nordisk (NVO) is slated to report second-quarter 2024 results on Aug 7, before the opening bell. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is pegged at $9.91 billion, while the same for earnings is pinned at 76 cents per share.In the past 30 days, the estimates for Novo Nordisk’s 2024 earnings per share (EPS) deteriorated from $3.41 to $3.38. During the same time frame, the forecast for the company’s 2025 EPS has improved from $4.30 to $4.35.Image Source: Zacks I ...

Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy.Novo Nordisk's blockbuster Wegovy weight loss drug has received backing from the European Union's medical regulator to expand the medicine's use to include reducing the rise of serious heart events in overweight and obese adults.The Danish pharmaceutical giant on Thursday said that the European Medical Agency had adopted a "positive opinion" on the label expansion after reviewing the outcomes of a closely watched SELECT trial, opening t ...

LONDON — The U.K.'s health regulator on Tuesday approved the use of Novo Nordisk's Wegovy weight loss drug to reduce the risk of overweight and obese adults suffering from serious heart problems or strokes.The new approval from the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) makes the Danish pharmaceutical giant's GLP-1 obesity drug the first in the country to be prescribed for prevention of cardiovascular events in people with obesity.It follows similar label expansion by the U.S. Foo ...